Standard BioTools terminated its previously announced agreement to sell its mass cytometry business to Multiplex Bio and entered into a new definitive Share and Asset Purchase Agreement with Element Biosystems, LLC, a subsidiary of GMT Venture Partners. The company agreed to pay Multiplex Bio a $1.5 million termination fee, of which GMT Venture contributed $1.0 million on the Company’s behalf. Under the new agreement, Element will acquire the business for an aggregate purchase price of $5.5 million in cash, payable at closing subject to customary adjustments and without the obligation to provide a $10 million working capital loan required by the terminated deal. The transaction is expected to close by the end of 2026, substantially concurrently with the Company’s pending merger with Treeline Biosciences, contingent upon stockholder approval and other conditions. Standard BioTools Inc. operates in the life science tools industry, providing next-generation solutions for biomedical research.
